Screener
Recursion Pharmaceuticals, Inc. RXRX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| Line item | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Accrued development expense | (814) | (155) |
| Accrued expenses and other current liabilities | (12,623) | (15,213) |
| Lease liabilities | (9,290) | (10,908) |
| Net cash used in operating activities | (187,048) | (208,375) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (302) | (4,982) |
| Purchase of an intangible asset | (1,995) | (2,158) |
| Decrease in cash related to disposal of a business | — | (4,438) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s operating cash flow?
- Recursion Pharmaceuticals, Inc. (RXRX) reported operating cash flow of -$105.95M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s operating cash flow changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s operating cash flow decreased by 38.6% year-over-year, from -$76.42M to -$105.95M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s operating cash flow?
- Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s operating cash flow has grown at a 23.7% compound annual growth rate (CAGR), from -$158.61M to -$371.81M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Recursion Pharmaceuticals, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude